AdvanCell: Scaling up lead-212 production, keeping down tox

Alpha-emitting radiopharmaceuticals pack a punch, promising precision tumor killing by delivering  high doses of radiation over short distances, but complex production and distribution remain a hurdle. Australia-based newco AdvanCell believes it has solved those problems and hopes to be first to bring the alpha-emitter lead-212 into large patient populations. 

The company, founded in 2019 by CEO Andrew Adamovich, has had a surge of activity this year, reporting Phase Ib data from its lead-212-based prostate cancer therapy, announcing a strategic collaboration with Eli Lilly and Co. (NYSE:LLY), and raising an oversubscribed $125 million series C round...